Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer

Neoantigens are ideal targets for dendritic cell (DC) vaccines. So far, only a few neoantigen-based DC vaccines have been investigated in clinical trials. Here, we reported a case of a patient with metastatic gastric cancer who received personalized neoantigen-loaded monocyte-derived dendritic cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Zengqing, Yuan, Yuan, Chen, Chao, Lin, Jing, Ma, Qiwang, Liu, Geng, Gao, Yan, Huang, Ying, Chen, Ling, Chen, Li-Zhu, Huang, Yu-Fang, Wang, Hailun, Li, Bo, Chen, Yu, Zhang, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166775/
https://www.ncbi.nlm.nih.gov/pubmed/35661819
http://dx.doi.org/10.1038/s41698-022-00279-3
_version_ 1784720681352560640
author Guo, Zengqing
Yuan, Yuan
Chen, Chao
Lin, Jing
Ma, Qiwang
Liu, Geng
Gao, Yan
Huang, Ying
Chen, Ling
Chen, Li-Zhu
Huang, Yu-Fang
Wang, Hailun
Li, Bo
Chen, Yu
Zhang, Xi
author_facet Guo, Zengqing
Yuan, Yuan
Chen, Chao
Lin, Jing
Ma, Qiwang
Liu, Geng
Gao, Yan
Huang, Ying
Chen, Ling
Chen, Li-Zhu
Huang, Yu-Fang
Wang, Hailun
Li, Bo
Chen, Yu
Zhang, Xi
author_sort Guo, Zengqing
collection PubMed
description Neoantigens are ideal targets for dendritic cell (DC) vaccines. So far, only a few neoantigen-based DC vaccines have been investigated in clinical trials. Here, we reported a case of a patient with metastatic gastric cancer who received personalized neoantigen-loaded monocyte-derived dendritic cell (Neo-MoDC) vaccines followed by combination therapy of the Neo-MoDC and immune checkpoint inhibitor (ICI). The patient developed T cell responses against neoantigens after receiving the Neo-MoDC vaccine alone. The following combination therapy triggered a stronger immune response and mediated complete regression of all tumors for over 25 months till October, 2021. Peripheral blood mononuclear cells recognized seven of the eight vaccine neoantigens. And the frequency of neoantigen-specific T cell clones increased obviously after vaccination. Overall, this report describing a complete tumor regression in a gastric cancer patient mediated by Neo-MoDC vaccine in combination with ICI, and suggesting a promising treatment for patients with metastatic gastric cancer.
format Online
Article
Text
id pubmed-9166775
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-91667752022-06-05 Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer Guo, Zengqing Yuan, Yuan Chen, Chao Lin, Jing Ma, Qiwang Liu, Geng Gao, Yan Huang, Ying Chen, Ling Chen, Li-Zhu Huang, Yu-Fang Wang, Hailun Li, Bo Chen, Yu Zhang, Xi NPJ Precis Oncol Case Report Neoantigens are ideal targets for dendritic cell (DC) vaccines. So far, only a few neoantigen-based DC vaccines have been investigated in clinical trials. Here, we reported a case of a patient with metastatic gastric cancer who received personalized neoantigen-loaded monocyte-derived dendritic cell (Neo-MoDC) vaccines followed by combination therapy of the Neo-MoDC and immune checkpoint inhibitor (ICI). The patient developed T cell responses against neoantigens after receiving the Neo-MoDC vaccine alone. The following combination therapy triggered a stronger immune response and mediated complete regression of all tumors for over 25 months till October, 2021. Peripheral blood mononuclear cells recognized seven of the eight vaccine neoantigens. And the frequency of neoantigen-specific T cell clones increased obviously after vaccination. Overall, this report describing a complete tumor regression in a gastric cancer patient mediated by Neo-MoDC vaccine in combination with ICI, and suggesting a promising treatment for patients with metastatic gastric cancer. Nature Publishing Group UK 2022-06-03 /pmc/articles/PMC9166775/ /pubmed/35661819 http://dx.doi.org/10.1038/s41698-022-00279-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Case Report
Guo, Zengqing
Yuan, Yuan
Chen, Chao
Lin, Jing
Ma, Qiwang
Liu, Geng
Gao, Yan
Huang, Ying
Chen, Ling
Chen, Li-Zhu
Huang, Yu-Fang
Wang, Hailun
Li, Bo
Chen, Yu
Zhang, Xi
Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer
title Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer
title_full Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer
title_fullStr Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer
title_full_unstemmed Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer
title_short Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer
title_sort durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-pd-1 therapy in metastatic gastric cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166775/
https://www.ncbi.nlm.nih.gov/pubmed/35661819
http://dx.doi.org/10.1038/s41698-022-00279-3
work_keys_str_mv AT guozengqing durablecompleteresponsetoneoantigenloadeddendriticcellvaccinefollowingantipd1therapyinmetastaticgastriccancer
AT yuanyuan durablecompleteresponsetoneoantigenloadeddendriticcellvaccinefollowingantipd1therapyinmetastaticgastriccancer
AT chenchao durablecompleteresponsetoneoantigenloadeddendriticcellvaccinefollowingantipd1therapyinmetastaticgastriccancer
AT linjing durablecompleteresponsetoneoantigenloadeddendriticcellvaccinefollowingantipd1therapyinmetastaticgastriccancer
AT maqiwang durablecompleteresponsetoneoantigenloadeddendriticcellvaccinefollowingantipd1therapyinmetastaticgastriccancer
AT liugeng durablecompleteresponsetoneoantigenloadeddendriticcellvaccinefollowingantipd1therapyinmetastaticgastriccancer
AT gaoyan durablecompleteresponsetoneoantigenloadeddendriticcellvaccinefollowingantipd1therapyinmetastaticgastriccancer
AT huangying durablecompleteresponsetoneoantigenloadeddendriticcellvaccinefollowingantipd1therapyinmetastaticgastriccancer
AT chenling durablecompleteresponsetoneoantigenloadeddendriticcellvaccinefollowingantipd1therapyinmetastaticgastriccancer
AT chenlizhu durablecompleteresponsetoneoantigenloadeddendriticcellvaccinefollowingantipd1therapyinmetastaticgastriccancer
AT huangyufang durablecompleteresponsetoneoantigenloadeddendriticcellvaccinefollowingantipd1therapyinmetastaticgastriccancer
AT wanghailun durablecompleteresponsetoneoantigenloadeddendriticcellvaccinefollowingantipd1therapyinmetastaticgastriccancer
AT libo durablecompleteresponsetoneoantigenloadeddendriticcellvaccinefollowingantipd1therapyinmetastaticgastriccancer
AT chenyu durablecompleteresponsetoneoantigenloadeddendriticcellvaccinefollowingantipd1therapyinmetastaticgastriccancer
AT zhangxi durablecompleteresponsetoneoantigenloadeddendriticcellvaccinefollowingantipd1therapyinmetastaticgastriccancer

Ejemplares similares